Literature DB >> 16900364

[Stage appropriate therapy for COPD].

H Hamm1.   

Abstract

The treatment of chronic obstructive pulmonary disease (COPD) has improved substantially over recent years, and is increasingly based on evidence from prospective studies. Cessation of smoking is the most important and effective single measure which can be taken. In the early stages, intensive measures for nicotine withdrawal should be taken to prevent the catastrophic effects of disease progression. Pharmacological treatment of COPD in the earlier stages (0-II) should be symptom oriented. Asymptomatic patients at these stages do not require permanent pharmacotherapy. From Stage II, COPD patients benefit from pulmonary rehabilitation programs. Patients with stages III and IV should usually be put on long-term corticosteroid inhalation, preferably in combination with long-acting bronchodilators. Systemic corticosteroids, even at low doses, are not indicated. They are useful only for the short-term treatment of acute exacerbations. These treatment modalities improve the quality of life and morbidity of COPD patients. They also decrease exacerbations and hospitalization rates, which should help to reduce mortality due to this important disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16900364     DOI: 10.1007/s00108-006-1701-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

1.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.

Authors:  L Davies; R M Angus; P M Calverley
Journal:  Lancet       Date:  1999-08-07       Impact factor: 79.321

Review 2.  Pulmonary rehabilitation in chronic obstructive pulmonary disease.

Authors:  Thierry Troosters; Richard Casaburi; Rik Gosselink; Marc Decramer
Journal:  Am J Respir Crit Care Med       Date:  2005-03-18       Impact factor: 21.405

Review 3.  Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.

Authors:  Ian M Adcock; Kazuhiro Ito
Journal:  Proc Am Thorac Soc       Date:  2005

4.  Bronchodilator response in the lung health study over 11 yrs.

Authors:  N R Anthonisen; P G Lindgren; D P Tashkin; R E Kanner; P D Scanlon; J E Connett
Journal:  Eur Respir J       Date:  2005-07       Impact factor: 16.671

5.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

6.  Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease.

Authors:  D D Sin; J V Tu
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

7.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

Authors:  J A van Noord; J-L Aumann; E Janssens; J J Smeets; J Verhaert; B Disse; A Mueller; P J G Cornelissen
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

8.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

Authors:  P L Paggiaro; R Dahle; I Bakran; L Frith; K Hollingworth; J Efthimiou
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

9.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

Authors:  W Szafranski; A Cukier; A Ramirez; G Menga; R Sansores; S Nahabedian; S Peterson; H Olsson
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

10.  Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis.

Authors:  E R Sutherland; H Allmers; N T Ayas; A J Venn; R J Martin
Journal:  Thorax       Date:  2003-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.